WILMINGTON, Mass., Nov. 14, 2014 /PRNewswire/ -- Implant Sciences
Corporation (OTCQB: IMSC), a high technology supplier of systems
and sensors for homeland security and defense markets, announced
today it will conduct a press conference on Monday, November 17, 2014 at 10:30 am ET at the Marriott Marquis Times Square,
New York City. Implant Sciences
will discuss significant recent Company events and will conduct
live demonstrations of the QS-B220, which is the first
non-radioactive explosives trace detector (ETD) to be approved for
baggage and passenger screening by the TSA.
A live webcast of the press conference will be available at the
following link: http://www.wsw.com/webcast/cc/imsc/
Members of media interested in attending the event may
contact: Janet Vasquez at 212-645-5498 or
jvasquez@jvprny.com.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing
advanced detection capabilities to counter and eliminate the
ever-evolving threats from explosives and drugs. The Company's team
of dedicated trace detection experts has developed proprietary
technologies used in its commercial products, thousands of which
have been sold across more than 50 countries worldwide. Implant
Sciences is only the third manufacturer, and the sole
American-owned company, to currently have an ETD system named as a
Qualified Product by the US Transportation Security Administration.
The Company's ETDs have received approvals and certifications from
several international regulatory agencies including the TSA in the
U.S., ECAC in Europe, STAC in
France, the German Ministry of the
Interior, and the Ministry of Public Safety in China. It also received a GSN 2013 Homeland
Security Award for "Best Explosives Detection Solution". All
Implant Sciences products are recognized as Qualified
Anti-Terrorism Technologies by the Department of Homeland Security.
For further details on the Company and its products, please visit
the Company's website at www.implantsciences.com.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700
or
Investor Contact:
Laurel Moody
646-810-0608
SOURCE Implant Sciences Corporation